Vaccines

BLOOMBERG       by  Matthew Hill                        Jan. 12, 2015                                    

At 4:50 a.m. at the Kasanka National Park in northern Zambia, tourists watch from a platform in a tree as the sound of millions of wings accompanies the sunrise.

Straw-coloured Fruit Bats fly in Kasanka National Park, Zambia. Photographer: Fabian von Poser/Getty Images

CENTER FOR INFECTIOUS DISEASE AND POLICY RESEARCH     by Lisa Schnirring                                 Jan. 9, 2015

The next steps in testing Ebola vaccines as well as a picture of how they might be used in West Africa's outbreak region became clearer today as officials from the World Health Organization (WHO) shared the outcome of yesterday's (Thursday's) high-level meeting in Geneva.

Large phase 3 trials in West Africa's outbreak setting will be next up to see if the vaccines work, with the studies designed to collect more safety data, a task usually covered in phase 2 trials, experts involved in the meeting said today at a WHO media telebriefing. However, as Ebola infections drop off in the outbreak region, scientists face a closing window of opportunity to see how the vaccines perform in a real-life setting.

Experts also signaled a possible role for two Ebola vaccine formulations: a single-dose vaccine providing shorter-term immunity that could be used to tamp down Ebola flare-ups and a prime-boost vaccine that may provide more durable immunity and could be used for other immunization strategies.

ASSOCIATED PRESS  by Maria Cheng                                                                          Jan. 9, 2015
LONDON --The World Health Organizationsays the two leading Ebola vaccines appear safe and will soon be tested in healthy volunteers in West Africa.

After an expert meeting this week, WHO said there is now enough information to conclude that the two most advanced Ebola vaccines ? one made by GlaxoSmithKline and the other licensed by Merck and NewLink ? have "an acceptable safety profile."

In a press briefing on Friday, Dr. Marie-Paule Kieny, who heads WHO's Ebola vaccine efforts, said "the cupboard (for Ebola vaccines) is filling up rapidly."

She said further trials in healthy people in West Africa, including health workers, are scheduled to start soon. Kieny added several other vaccines were being developed in the U.S., Russia and elsewhere.

Read complete story.
http://abcnews.go.com/Health/wireStory/leading-ebola-vaccines-safe-tests-starting-28107527

THE DAILY BEAST  by Abby Haglage                                                                  Jan. 7, 2015

...Although a few smaller companies have become involved in the race for a vaccine, three major pharmaceutical makers are taking the lead—each pursuing a different vaccine. The trials are unprecedented for a variety of reasons, including the rapid timeline (trials of this nature generally take three to four years).

                                                      Steve Parsons-WPA Pool/Getty Images

Each individual race involves an unusual collaboration between researchers, manufacturers, and public-health entities. Together, the teams are working 24 hours a day for a product that promises much higher risk than it does profit.

Here’s what you need to know about the Ebola vaccine front-runners.

Read complete story.

http://www.thedailybeast.com/articles/2015/01/07/the-race-for-the-ebola-vaccine.html